Skip to content

For laboratory research use only — not for human or veterinary use

Compound comparison

Retatrutide vs Tirzepatide

Both are synthetic incretin-class peptides studied as reference materials in metabolic and receptor-signaling research. The headline difference is how many receptors each targets — tirzepatide is a dual GIP/GLP-1 agonist, while retatrutide adds a third (glucagon) receptor. Supplied for laboratory research use only; not for human or veterinary use.

Retatrutide Tirzepatide
Compound class Triple receptor agonist Dual receptor agonist
Receptor targets GLP-1 · GIP · glucagon (GCGR) GIP · GLP-1
Developer code LY3437943 LY3298176
Molecular formula C221H342N46O68 C225H348N48O68
Molecular weight ≈ 4731.33 Da ≈ 4813.45 Da
CAS number 2381089-83-2 2023788-19-2
Primary research area Multi-receptor metabolic research Incretin / metabolic research
Format at TagPep 60 mg lyophilized research vial 60 mg lyophilized research vial

Molecular data verified against PubChem and published literature. Molecular weights are average values.

The mechanism difference

Both compounds engage the GIP and GLP-1 receptors. The distinction is the third pathway: retatrutide also acts on the glucagon (GCGR) receptor, which is why it is described as a triple agonist and tirzepatide as a dual agonist. In laboratory research, that added glucagon-receptor activity is the primary variable investigators compare between the two.

Research context

Each is an investigational synthetic peptide used as a well-characterized reference material in metabolic, incretin and receptor-signaling research. Identity and reported purity are confirmed by batch-specific analytical documentation. For background see the multi-receptor agonist primer and the research-peptide reference table.

Common questions

What is the difference between retatrutide and tirzepatide?

The defining difference is receptor coverage. Tirzepatide is a dual agonist that engages the GIP and GLP-1 receptors. Retatrutide is a triple agonist that engages GLP-1 and GIP and additionally the glucagon (GCGR) receptor. Both are synthetic incretin-class peptides supplied for laboratory research use only.

Are retatrutide and tirzepatide in the same class?

Both are multi-receptor incretin-based peptides studied in metabolic and receptor-signaling research. Tirzepatide (dual GIP/GLP-1) and retatrutide (triple GLP-1/GIP/glucagon) differ in how many receptor pathways they target, which is the main axis researchers compare.

Can I buy retatrutide and tirzepatide for research?

Yes. TagPep supplies both as lyophilized reference vials (60 mg) with batch-specific analytical documentation, for laboratory research use only — not for human or veterinary use. See the product pages linked above.

Related comparisons

Research-use notice

This comparison is factual reference information for laboratory research and educational use. Both compounds are research materials supplied for laboratory research use only — not for human or veterinary use, consumption, injection, administration, diagnosis, or treatment. No dosing or administration guidance is provided or implied.